328 related articles for article (PubMed ID: 27409164)
1. MiR-27a-3p functions as an oncogene in gastric cancer by targeting BTG2.
Zhou L; Liang X; Zhang L; Yang L; Nagao N; Wu H; Liu C; Lin S; Cai G; Liu J
Oncotarget; 2016 Aug; 7(32):51943-51954. PubMed ID: 27409164
[TBL] [Abstract][Full Text] [Related]
2. MiR-25-3p promotes the proliferation of triple negative breast cancer by targeting BTG2.
Chen H; Pan H; Qian Y; Zhou W; Liu X
Mol Cancer; 2018 Jan; 17(1):4. PubMed ID: 29310680
[TBL] [Abstract][Full Text] [Related]
3. MiR-6875-3p promotes the proliferation, invasion and metastasis of hepatocellular carcinoma via BTG2/FAK/Akt pathway.
Xie Y; Du J; Liu Z; Zhang D; Yao X; Yang Y
J Exp Clin Cancer Res; 2019 Jan; 38(1):7. PubMed ID: 30621734
[TBL] [Abstract][Full Text] [Related]
4. Extracellular vesicles carry miR-27a-3p to promote drug resistance of glioblastoma to temozolomide by targeting BTG2.
Chen L; Li Z; Hu S; Deng Q; Hao P; Guo S
Cancer Chemother Pharmacol; 2022 Feb; 89(2):217-229. PubMed ID: 35039898
[TBL] [Abstract][Full Text] [Related]
5. LINC01089 inhibits the progression of cervical cancer via inhibiting miR-27a-3p and increasing BTG2.
Li S; Han Y; Liang X; Zhao M
J Gene Med; 2021 Jan; 23(1):e3280. PubMed ID: 33025678
[TBL] [Abstract][Full Text] [Related]
6. miR‑27a suppresses the clonogenic growth and migration of human glioblastoma multiforme cells by targeting BTG2.
Li WQ; Yu HY; Zhong NZ; Hou LJ; Li YM; He J; Liu HM; Xia CY; Lu YC
Int J Oncol; 2015 Apr; 46(4):1601-8. PubMed ID: 25626081
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-542-3p suppresses cell growth of gastric cancer cells via targeting oncogene astrocyte-elevated gene-1.
Shen X; Si Y; Yang Z; Wang Q; Yuan J; Zhang X
Med Oncol; 2015 Jan; 32(1):361. PubMed ID: 25432696
[TBL] [Abstract][Full Text] [Related]
8. Pancreatic cancer cell-derived exosomal microRNA-27a promotes angiogenesis of human microvascular endothelial cells in pancreatic cancer via BTG2.
Shang D; Xie C; Hu J; Tan J; Yuan Y; Liu Z; Yang Z
J Cell Mol Med; 2020 Jan; 24(1):588-604. PubMed ID: 31724333
[TBL] [Abstract][Full Text] [Related]
9. miR-21 regulates N-methyl-N-nitro-N'-nitrosoguanidine-induced gastric tumorigenesis by targeting FASLG and BTG2.
Yang Q; Xu E; Dai J; Wu J; Zhang S; Peng B; Jiang Y
Toxicol Lett; 2014 Aug; 228(3):147-56. PubMed ID: 24821435
[TBL] [Abstract][Full Text] [Related]
10. MiR-199a/b-3p inhibits gastric cancer cell proliferation via down-regulating PAK4/MEK/ERK signaling pathway.
Zeng B; Shi W; Tan G
BMC Cancer; 2018 Jan; 18(1):34. PubMed ID: 29304764
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-27a contributes to the malignant behavior of gastric cancer cells by directly targeting PH domain and leucine-rich repeat protein phosphatase 2.
Ding L; Zhang S; Xu M; Zhang R; Sui P; Yang Q
J Exp Clin Cancer Res; 2017 Mar; 36(1):45. PubMed ID: 28327189
[TBL] [Abstract][Full Text] [Related]
12. miR-27a-3p regulates proliferation and apoptosis of colon cancer cells by potentially targeting BTG1.
Su C; Huang DP; Liu JW; Liu WY; Cao YO
Oncol Lett; 2019 Sep; 18(3):2825-2834. PubMed ID: 31452761
[TBL] [Abstract][Full Text] [Related]
13. miR-487a performs oncogenic functions in osteosarcoma by targeting BTG2 mRNA.
Gu Z; Wu S; Xu G; Wu W; Mao B; Zhao S
Acta Biochim Biophys Sin (Shanghai); 2020 Jun; 52(6):631-637. PubMed ID: 32409840
[TBL] [Abstract][Full Text] [Related]
14. The oncogenic miR-27a/BTG2 axis promotes obesity-associated hepatocellular carcinoma by mediating mitochondrial dysfunction.
Su Q; Xu ZX; Xiong ML; Li HY; Xu MY; Luo SZ
Neoplasma; 2022 Jul; 69(4):820-831. PubMed ID: 35532294
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-27a-3p Reverses Adriamycin Resistance by Targeting BTG2 and Activating PI3K/Akt Pathway in Breast Cancer Cells.
Zhu B; Chen W; Fu Y; Cui X; Jin L; Chao J; Yun X; Gao P; Shan S; Li J; Yin X; Zhu C; Qin X
Onco Targets Ther; 2020; 13():6873-6884. PubMed ID: 32764979
[TBL] [Abstract][Full Text] [Related]
16. Low abundance of TFPI-2 by both promoter methylation and miR-27a-3p regulation is linked with poor clinical outcome in gastric cancer.
Geng G; Liu X; Xu A; Lu Z; Chen K; He J; Qi D; Yuan X
J Gene Med; 2020 May; 22(5):e3166. PubMed ID: 31984574
[TBL] [Abstract][Full Text] [Related]
17. miR-338-3p suppresses gastric cancer progression through a PTEN-AKT axis by targeting P-REX2a.
Guo B; Liu L; Yao J; Ma R; Chang D; Li Z; Song T; Huang C
Mol Cancer Res; 2014 Mar; 12(3):313-21. PubMed ID: 24375644
[TBL] [Abstract][Full Text] [Related]
18. miR-615-3p promotes proliferation and migration and inhibits apoptosis through its potential target CELF2 in gastric cancer.
Wang J; Liu L; Sun Y; Xue Y; Qu J; Pan S; Li H; Qu H; Wang J; Zhang J
Biomed Pharmacother; 2018 May; 101():406-413. PubMed ID: 29501762
[TBL] [Abstract][Full Text] [Related]
19. BTG2: a rising star of tumor suppressors (review).
Mao B; Zhang Z; Wang G
Int J Oncol; 2015 Feb; 46(2):459-64. PubMed ID: 25405282
[TBL] [Abstract][Full Text] [Related]
20. Circular RNA circFLNA inhibits the development of bladder carcinoma through microRNA miR-216a-3p/BTG2 axis.
Lin S; Wang L; Shi Z; Zhu A; Zhang G; Hong Z; Cheng C
Bioengineered; 2021 Dec; 12(2):11376-11389. PubMed ID: 34852712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
